Amer Zeidan, MBBS, MD
Professor of Medicine (Hematology) — Yale School of Medicine
Dr. Zeidan is Chief of the Division of Hematologic Malignancies and Director of Early Therapeutics Research and the Leukemia and Myeloid Malignancies Program at Yale Cancer Center. He specializes in myeloid malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia, with research focused on novel targeted and immunotherapy-based treatments. He earned his MBBS from the University of Jordan, completed residency at Rochester General Hospital, and hematology/oncology fellowship at Johns Hopkins Hospital, where he also earned an MHS in Clinical Investigation. He has authored more than 360 peer-reviewed publications and received multiple national research awards.
Areas of Focus: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancies, Early-Phase Clinical Trials, Immunotherapy
Latest Content
Videos & Podcasts
08/18/2026
Navigating Frontline Treatment and Disease Progression in Myelodysplastic Syndromes
Evolving Approaches: Low-Risk MDS
08/07/2026
Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes
Evolving Approaches: Low-Risk MDS
08/04/2026
Ep. 3: Managing Imetelstat Toxicities in Lower-Risk MDS
Evolving Approaches: Low-Risk MDS
08/01/2026
Ep. 2: Imetelstat, Luspatercept, and ESAs: Treatment Sequencing in Lower-Risk MDS
Evolving Approaches: Low-Risk MDS
07/29/2026
Ep. 1: The Growing Role of Next-Generation Sequencing and IPSS-M in Lower-Risk MDS
Evolving Approaches: Low-Risk MDS
07/28/2026
The Role of Imetelstat in Lower-Risk Myelodysplastic Syndromes
Luspatercept in Low-Risk MDS
06/24/2026